Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has issued a correction disclosure extending the disclosure postponement period and specifying the contract end date to December 31, 2028, at the customer’s request regarding the contract manufacturing agreement originally disclosed on August 14, 2018.
📊 [Key Disclosure Details & Financial Figures]
- Original Filing & Submission Date: Single Sales and Supply Contract (Submitted on August 14, 2018)
- Reason for Correction: Extension of disclosure postponement period at the customer’s request
- Key Correction Items:
- Contract Period End Date: (Before) Unstated (-) → (After) December 31, 2028
- Contract Terms (Advance Payment): (Before) Unstated (-) → (After) None
- Disclosure Postponement Reason: (Before) Unstated (-) → (After) Business confidentiality
- Disclosure Postponement Period: (Before) December 31, 2025 → (After) December 31, 2028
- Contract Overview (Based on Original Filing):
- Contract Title: Pharmaceutical Contract Manufacturing Agreement
- Contract Amount: KRW 144,610,010,460 (USD 127,555,800 / Based on confirmed minimum guaranteed amount, applied exchange rate KRW 1,133.70 per USD)
- Recent Annual Revenue: KRW 464,629,334,143 (Based on FY2017 consolidated financial statements)
- Contract Amount to Revenue Ratio: 31.12%
- Counterparty: Pharmaceutical company based in Asia
- Contract Period: August 14, 2018 – December 31, 2028
- Contract Date: August 14, 2018
- Other Important Investment Details:
- The confirmed minimum guaranteed contract amount may increase upon mutual agreement if customer demand grows.
- The contract end date and contract amount are subject to change upon mutual agreement.
- Counterparty identity is slated for disclosure on December 31, 2028, due to business confidentiality, subject to future changes.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Tracking Disclosure Timelines and Changes Following Postponement Extension
This correction disclosure updates the confidentiality postponement period and contract end date for the contract manufacturing deal with an Asian pharmaceutical company to December 31, 2028.
Checking the adjusted disclosure timeline and potential contract amount updates is crucial for understanding the ongoing structure and progress of the contract.
Relevant developments can be verified upon the expiration of the extended postponement period (December 31, 2028) or through subsequent correction disclosures and periodic reports.
📢 Disclaimer & Source Notice
Source: This content was structured and regenerated based on official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Warning: This content is provided solely for informational and educational purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
